Trial document





This study has been imported from ClinicalTrials.gov without additional data checks.
drksid header

  DRKS00006386

Trial Description

start of 1:1-Block title

Title

A Randomized, Double-blind, Event-driven, Placebo-controlled, Multicenter Study of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Subjects With Type 2 Diabetes Mellitus and Diabetic Nephropathy

end of 1:1-Block title
start of 1:1-Block acronym

Trial Acronym

CREDENCE

end of 1:1-Block acronym
start of 1:1-Block url

URL of the Trial

[---]*

end of 1:1-Block url
start of 1:1-Block public summary

Brief Summary in Lay Language

The goal of this study is to assess whether canagliflozin has a renal and vascular
protective effect in reducing the progression of renal impairment relative to placebo in
participants with type 2 diabetes mellitus (T2DM), Stage 2 or 3 chronic kidney disease (CKD)
and macroalbuminuria, who are receiving standard of care including a maximum tolerated
labeled daily dose of an angiotensin-converting enzyme inhibitor (ACEi) or angiotensin
receptor blocker (ARB).

end of 1:1-Block public summary
start of 1:1-Block scientific synopsis

Brief Summary in Scientific Language

This is a randomized (the study medication is assigned by chance), double-blind (neither
physician nor participant knows the identity of the assigned treatment), placebo-controlled
(an inactive substance that is compared with a medication to test whether the medication has
a real effect), parallel-group, multicenter study of the effects of canagliflozin on renal
and cardiovascular outcomes in participants with type 2 diabetes mellitus (T2DM) and
diabetic nephropathy, who are receiving standard of care including a maximum tolerated daily
dose of an angiotensin-converting enzyme inhibitor (ACEi) or angiotensin receptor blocker
(ARB).

The study will consist of a pretreatment phase (several weeks), and a double-blind treatment
phase (up to 66 months). During the pretreatment phase all participants will also receive
diet/exercise counseling for lipid and blood pressure management as well as counseling on
renal and cardiovascular (CV) risk factor medication. A post-treatment follow-up contact or
visit will take place approximately 30 days after the last dose of study drug or the
completion of the study. The total duration of the study is estimated to be about 5.5 years.
Approximately 3,700 participants will be randomized in a 1:1 ratio to canagliflozin or
matching placebo. Participants randomized to canagliflozin will receive a dose of 100 mg
once daily. The overall safety and tolerability of canagliflozin will be evaluated by
collecting information on adverse events, laboratory tests, vital signs (pulse, blood
pressure), physical examination, and body weight.

end of 1:1-Block scientific synopsis
start of 1:1-Block organizational data

Organizational Data

  •   DRKS00006386
  •   2014/11/17
  •   2014/02/17
  •   no
  •   [---]*
  •   [---]*
end of 1:1-Block organizational data
start of 1:n-Block secondary IDs

Secondary IDs

  •   2013-004494-28 
  •   NCT02065791  (ClinicalTrials.gov)
  •   CR103517  (Janssen Research & Development, LLC)
  •   2013-004494-28 
  •   28431754DNE3001 
end of 1:n-Block secondary IDs
start of 1:N-Block indications

Health Condition or Problem studied

  •   Diabetes Mellitus, Type 2
  •   Diabetic Nephropathies
  •   E11.2 -  Non-insulin-dependent diabetes mellitus; With renal complications
  •   N08.3 -  Glomerular disorders in diabetes mellitus
end of 1:N-Block indications
start of 1:N-Block interventions

Interventions/Observational Groups

  •   Drug: Canagliflozin
  •   Drug: Placebo
end of 1:N-Block interventions
start of 1:1-Block design

Characteristics

  •   Interventional
  •   [---]*
  •   Randomized controlled trial
  •   Blinded
  •   patient/subject, investigator/therapist
  •   Placebo
  •   Treatment
  •   Parallel
  •   III
  •   [---]*
end of 1:1-Block design
start of 1:1-Block primary endpoint

Primary Outcome

- Time to the first occurrence of an event in the primary composite endpoint; time frame: Baseline, up to Month 66; The primary composite endpoint of the study includes end-stage kidney disease (ESKD), doubling of serum creatinine, renal or cardiovascular (CV) death.

end of 1:1-Block primary endpoint
start of 1:1-Block secondary endpoint

Secondary Outcome

- Time to the first occurrence of an event in the CV composite endpoint; time frame: Baseline, up to Month 66; The CV composite endpoint includes CV death, non-fatal myocardial infarction (MI), non-fatal stroke, hospitalized congestive heart failure and hospitalized unstable angina.
- Time to the first occurrence of an event in the renal composite endpoint; time frame: Baseline, up to Month 66; The renal composite endpoint includes ESKD, doubling of serum creatinine, and renal death.
- Time to all-cause death; time frame: Baseline, up to Month 66; All deaths occurring during the study from any cause.

end of 1:1-Block secondary endpoint
start of 1:n-Block recruitment countries

Countries of Recruitment

  •   United States
  •   Argentina
  •   Australia
  •   Bulgaria
  •   Canada
  •   Czech Republic
  •   Germany
  •   Hong Kong
  •   Hungary
  •   Korea, Republic of
  •   Malaysia
  •   Mexico
  •   New Zealand
  •   Philippines
  •   Poland
  •   Romania
  •   Russian Federation
  •   South Africa
  •   Spain
  •   Ukraine
  •   United Kingdom
end of 1:n-Block recruitment countries
start of 1:n-Block recruitment locations

Locations of Recruitment

  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
end of 1:n-Block recruitment locations
start of 1:1-Block recruitment

Recruitment

  •   [---]*
  •   2014/02/27
  •   3700
  •   Multicenter trial
  •   International
end of 1:1-Block recruitment
start of 1:1-Block inclusion criteria

Inclusion Criteria

  •   Both, male and female
  •   30   Years
  •   no maximum age
end of 1:1-Block inclusion criteria
start of 1:1-Block inclusion criteria add

Additional Inclusion Criteria

- Type 2 diabetes mellitus with an HbA1c >= 6.5% and <=10.5%, with an estimated
glomerular filtration rate (eGFR) of >= 30 and < 90 mL/min/1.73m2

- Participants need to be on a maximum tolerated labeled daily dose of an
angiotensin-converting enzyme inhibitor (ACEi) or angiotensin receptor blocker (ARB)
for at least 4 weeks prior to randomization

- Must have a urine albumin to creatinine ratio (UACR) of > 300 mg/g and <= 5000 mg/g

end of 1:1-Block inclusion criteria add
start of 1:1-Block exclusion criteria

Exclusion Criteria

- History of diabetic ketoacidosis or type 1 diabetes mellitus

- History of hereditary glucose-galactose malabsorption or primary renal glucosuria

- Renal disease that required treatment with immunosuppressive therapy

- Known significant liver disease

- Current or history of New York Heart Association (NYHA) Class IV heart failure

end of 1:1-Block exclusion criteria
start of 1:n-Block addresses

Addresses

  • start of 1:1-Block address primary-sponsor
    • Janssen Research & Development, LLC
    end of 1:1-Block address primary-sponsor
    start of 1:1-Block address contact primary-sponsor
    •   [---]*
    •   [---]*
    •   [---]*
    •   [---]*
    end of 1:1-Block address contact primary-sponsor
  • start of 1:1-Block address other
    • The George Institute for Global Health, Australia
    end of 1:1-Block address other
    start of 1:1-Block address contact other
    •   [---]*
    •   [---]*
    •   [---]*
    •   [---]*
    end of 1:1-Block address contact other
  • start of 1:1-Block address scientific-contact
    • Janssen Research & Development, LLC
    • Janssen Research & Development, LLC Clinical Trial 
    end of 1:1-Block address scientific-contact
    start of 1:1-Block address contact scientific-contact
    •   [---]*
    •   [---]*
    •   [---]*
    •   [---]*
    end of 1:1-Block address contact scientific-contact
  • start of 1:1-Block address public-contact
    • Use link at the bottom of the page to see if you qualify for an enrolling site (see list). If you still have questions: 
    end of 1:1-Block address public-contact
    start of 1:1-Block address contact public-contact
    end of 1:1-Block address contact public-contact
end of 1:n-Block addresses
start of 1:n-Block material support

Sources of Monetary or Material Support

  • start of 1:1-Block address materialSupport
    • Bitte wenden Sie sich an den Sponsor / Please refer to primary sponsor
    end of 1:1-Block address materialSupport
    start of 1:1-Block address contact materialSupport
    •   [---]*
    •   [---]*
    •   [---]*
    •   [---]*
    end of 1:1-Block address contact materialSupport
end of 1:n-Block material support
start of 1:1-Block state

Status

  •   Recruiting ongoing
  •   [---]*
end of 1:1-Block state
start of 1:n-Block publications

Trial Publications, Results and other Documents

end of 1:n-Block publications
The parameters in ClinicalTrials.gov and DRKS are not identical. Therefore the data import from ClinicalTrials.gov required adjustments. For full details please see the DRKS FAQs .
  •   2
  •   2014/12/02
* This entry means the parameter is not applicable or has not been set.